RamonaPerformance Dashboard
Q2 2026 Last updated June 23, 2026
Salesforce · Hiring · Financials · Support — auto-detected Last upload: Jun 23, 12:26 PM

Company Performance

Quarter-to-date metrics across revenue, team growth, burn, and customer health

YTD Commercial Revenue
$1.423M
↑ 18% YTD vs full-year 2025
Target: $3.3M
43% to target revenueOperationsFinance
Total Pipeline
$22.9M
↑ 2.3× vs prior quarter
77 active opportunities
$297K avg deal sizeCommercialSales
Gross Burn
$1.2M/mo
→ Net burn $862K/mo
Forecast: $1.4M/mo
32 months runwayOperationsFinance
Headcount
24 FTE
↑ 5 hires since close
Target: from hiring plan
65% of hiring planOperationsPeople Ops
Employee Satisfaction
87%
Q2 2026 survey
eNPS 27 · scale −100 to +100
40% prom · 47% pass · 13% detr
OperationsPeople Ops
CSAT (Happiness Rate)
100%
↑ Apr 30 – May 30, 2026
9 new, 10 closed, 1 on hold
No ratings recordedOperationsSupport
Install Base
61
↑ Growing install base
Systems deployed across all site types
31 active customer sitesOperationsSupport
Revenue vs Target
Quarterly recognized revenue — Kestrel + Vireo combined
CommercialSales
Actual
Target
Pipeline by Stage
Weighted opportunity count — current quarter
CommercialSales
Headcount Progression
FTE growth vs 2026 hiring plan
OperationsPeople Ops
Actual
Plan
NPS Trend
Annual Net Promoter Score, 3-year view
OperationsSupport

Revenue & Pipeline

Detailed commercial performance across products, segments, and pipeline stage

Pipeline stage gates & weights — what each stage means and its close probability
Verified Purchasing Intent 1%
Gate out: introductory customer call is scheduled.
Stage 1 — Discovery 5%
Gate out: customer agrees to evaluate the solution and a demo/evaluation plan is defined.
Stage 2 — Eval 20%
Gate out: demo/evaluation completed and customer confirms intent to purchase if requirements are met.
Stage 3 — Purchase Commitment 50%
Gate out: opportunity has entered the customer's procurement or purchasing process.
Stage 4 — Procurement 85%
Gate out: Purchase Order or equivalent purchasing document is issued.
Close-won 100%
Gate out: PO is received and order is booked.
Unweighted pipeline by product
Open pipeline value — Kestrel vs Vireo by stage
CommercialSales
Kestrel
Vireo
Weighted pipeline by close quarter
Open pipeline weighted by Board-deck gate probability, pending close-rate validation
CommercialSales
Top Opportunities
Largest open opportunities by value
CommercialSales
Account Product Stage Amount
BMS Vireo Stage 2 $1.3M
Bayer Crop Science Vireo Stage 2 $700K
Frederick National Laboratory Vireo Stage 4 $522K
Second Cell Bio Vireo Stage 1 $500K
Merck Vireo Stage 1 $300K
Aithyra Vireo Stage 2 $300K
AbbVie, Inc. Vireo Stage 2 $300K
Novartis Vireo Stage 2 $300K
Chan Zuckerberg Biohub Network Vireo Stage 2 $300K
Generate:Biomedicines Vireo VPI $280K

Finance

Burn, cash position, margin, and capital deployment

Burn Details
May 2026 snapshot
OperationsFinance
Cash remaining
$17.7M
Gross burn / month (current)
$1.2M
Forecasted gross burn / month (3 actual + 9 fcast)
$1.4M
Net burn / month (current)
$862K
Product gross margin (trailing 3 mth avg)
55%
Runway
32 months
Monthly Burn
Gross burn per month, trailing 12 months
OperationsFinance
Cash Position
Cash on hand since Series A close
OperationsFinance
Product Gross Margin Trend
Rolling 3-month product gross margin
OperationsFinance

Team & Hiring

Headcount, open roles, and 2026 hiring plan progress

Headcount by Function
Current distribution
OperationsPeople Ops
Hiring Plan — 2026
Filled vs active search vs planned by quarter
OperationsPeople Ops
Filled
Active search
Planned
Open Roles
Active searches and planned hires — 2026
OperationsPeople Ops
RoleFunctionReports ToTarget StartStatus
Data ScientistAssay DevJohn EfromsonJun 15, 2026Interviewing
Full-Stack Software EngineerEngineeringMark HarfoucheJul 13, 2026Interviewing
Software Engineer, System IntegrationEngineeringGregor HorstmeyerAug 1, 2026Interviewing
Solutions EngineerEngineeringGregor HorstmeyerJul 27, 2026Interviewing
Operations CoordinatorOperationsKelsey WorshamAug 10, 2026Interviewing
Machine Vision EngineerEngineeringMark HarfoucheAug 24, 2026Interviewing
Engineering Project ManagerEngineeringMark HarfoucheSep 7, 2026Interviewing
Marketing DirectorCommercialGregor HorstmeyerJul 6, 2026Prepping to post
Front-End EngineerEngineeringMark HarfoucheMay 25, 2026Not posted
Partnerships & Special ProjectsCommercialGregor HorstmeyerAug 1, 2026Not posted
Fractional CFOOperationsMargaret AerySep 21, 2026Not posted
Mechatronics EngineerEngineeringAurélien BègueOct 5, 2026Not posted
Optoelectronics Hardware EngineerEngineeringMark HarfoucheApr 20, 2026Offer extended
Org Chart
Reporting structure

Customer Health

Net Promoter Score and customer satisfaction

Net Promoter Score
Annual survey — 3-year avg (2023–2025)
OperationsSupport
78
3-Year Average
2023: 772024: 862025: 71
Happiness Rate
Zoho Helpdesk — last 30 days
OperationsSupport
100%
Customer Happiness Rate
Good 100%Okay 0%Bad 0%
NPS Trend — 3 years, 70+ each year
Annual score — 2023 (n=29), 2024 (n=14), 2025 (n=5)
OperationsSupport
Support Operations — Last 30 Days
Ticket volume and response performance
OperationsSupport
New Tickets
9
10 closed · 1 on hold · 0 backlog
First Response Time
4.1hrs avg
Avg across all tickets
Resolution Time
36.8hrs avg
Avg time to close
Low ticket volume reflects a small, stable install base. Zero overdue tickets and 100% happiness rate indicate strong post-sale responsiveness.
Cumulative Software Sessions
Total MCAM software entries since deployment — Jul 2024 to May 2026
EngineeringSoftware
Cumulative sessions
Monthly sessions
94,518 total sessions across 63 deployed systems. Accelerating usage curve indicates growing engagement with the installed base — customers are using the platform actively, not shelving it.

Company Goals

2026 themes, target outcomes, and quarterly execution

3-Year Goals
01
Lead the market in plate-based imaging instrumentation
Become the leading platform for life-science research and automated screening, from entry-level systems to high-throughput, high-resolution instruments.
02
Pioneer dynamic drug screening with video microscopy
Deliver the first dynamic, image-based drug screening assays powered by high-throughput video microscopy and real-time ML, evolving toward kit-based offerings.
03
Demonstrate behavioral phenotype-driven cell enrichment
Show selective enrichment of viable cells by behavioral phenotype captured through video microscopy, a new paradigm for functional cell selection.
Status at a glance
Theme Outcomes Overall Ahead On Risk Behind Done Open
T1Commercial & Scale5Not started5
T2Core Technology4Not started4
T3Biology4Not started4
T4Market Reach3Not started3
T5Operations5Not started5
T1
Commercial & Scale
Strengthen and standardize core workflows and scale the commercial and operational systems required for reliable delivery, so customers can onboard faster and revenue becomes more predictable.
Not started
Committee: Nathan, Kay, Julia, Waylin, Jarrett
Achieve $3M+ in revenue recognition
Details & activities
Achieve $3M+ in revenue recognition by December 2026, target $6M+ by end of 2027.
Quarterly activities
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Launch 3 validated Vireo application packages
Details & activities
Make a coordinated market push for Vireo in Q3 2026 with ≥3 fully supported, validated biological applications, each accompanied by Ramona-authored white papers, sales collateral, and training and implementation materials, along with progress toward 2 partner manuscripts.
Quarterly activities
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Establish accountable customer success and support ownership
Details & activities
Establish a single accountable owner for customer success and support by Q2 2026 to define service standards, resource and staff the function, manage escalations, and set clear internal and external expectations.
Quarterly activities
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Productize Vireo analysis: 3 workflows to beta
Details & activities
Productize Vireo analysis capabilities by advancing three discrete, supportable workflows through the product development matrix to at least beta release, enabling validation and packaging.
Quarterly activities
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Create external communication cadence to support market visibility
Details & activities
Lead a quarterly external communication cadence in 2026 that translates Ramona’s major technical advances and newly validated biological workflows into clear, data-backed market narratives, strengthening brand credibility and enabling sales.
Quarterly activities
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
T2
Core Technology
Advance the core performance of Ramona’s technology, resolution, speed, autofocus, and capture performance, to unlock higher-resolution, video-enabled biological workflows and expand the markets we serve.
Not started
Committee: Veton, Jed, Clay, Jason
Integrate 0.32 NA lenses into the Vireo
Details & activities
Integrate new higher-resolution lenses, 0.32 NA, into the Vireo and validate them through characterized brightfield performance, supported acquisition workflows, and a defined fluorescence path, enabling a commercially supported release in 2026.
Quarterly activities
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Validate parallelized sub-cellular resolution imaging
Details & activities
Validate parallelized sub-cellular resolution imaging with per-lens autofocus and integrated fluorescence capability across a ≥12-lens array, demonstrated through neuron imaging in fluorescence at SBI2 2026.
Quarterly activities
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Advance autofocus performance in production-relevant architecture
Activities
Quarterly activities
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Advance foundational software platform
Details & activities
Advance Ramona’s foundational software platform to support scalable access, data management, and external system integration, enabling future packaging and monetization while reducing operational friction as usage grows.
Quarterly activities
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
T3
Biology
Demonstrate Ramona’s ability to generate, process, and interpret time-lapse behavioral datasets at scale, anchored by one end-to-end assay with external validation and a reusable analysis pipeline.
Not started
Committee: Josh, Daniel, Kelly, John
Validate priority biological workflows for Vireo
Activities
Quarterly activities
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Assess and prioritize 2+ video-based biological assays
Details & activities
Assess and prioritize ≥2 high-value video-based biological assays enabled by Ramona’s improved resolution and autofocus capabilities, each supported by documented customer validation and a clear path to productization.
Quarterly activities
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Secure beta users for priority video assay workflows
Activities
Quarterly activities
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Demonstrate end-to-end plate-based single-cell behavioral profiling
Activities
Quarterly activities
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
T4
Market Reach
Expand Ramona’s reach by embedding our technology into partner systems through licensing, OEM integration, and co-development, with clear commercial models, technical readiness, and repeatable processes.
Not started
Committee: Aurélien, Nathan
Build and manage priority strategic partnerships
Activities
Quarterly activities
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Advance customer / collaborator relationships that validate key applications
Activities
Quarterly activities
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Use partnerships to amplify biological and commercial adoption
Activities
Quarterly activities
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
T5
Operations
Strengthen Ramona’s cultural, financial, and operational systems to support sustainable growth, ensuring clear ownership, measurable goals, consistent review cadence, and reliable infrastructure as the company scales.
Not started
Committee: Margaret, Kelsey, Aurélien, Gail
Execute facility move
Details & activities
Deliver a staged move into a scalable new facility before the July 2026 lease end, including lab + assembly build-out, ready-to-hire capacity, and clear ownership/budgets for each area, so teams are fully functional and settled without impacting research, production, or customer delivery.
Quarterly activities
Create the office move communication system
Complete early space planning / move staging work
Complete Pettigrew move-in with all teams settled in and working
Determine plan for dealing with remaining furniture at W Main and Pettigrew
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Execute 2026 hiring & onboarding plan
Details & activities
Deliver and execute a coordinated 2026 hiring and onboarding plan by February 2026, ensuring role clarity and cultural alignment through structured onboarding and use of Accountability Chart, GWC, and MVV in hiring and performance decisions.
Quarterly activities
Publish the 2026 hiring plan / headcount model
Run the hiring manager kickoff
Begin interviewing for and onboarding according to 2026 hiring plan
Update hiring execution view post-Series A
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Coordinate company-wide performance tracking
Details & activities
Coordinate company-wide performance tracking for 2026 themes and outcomes by defining metrics and accountable owners and facilitating monthly Scorecard reviews to support leadership decision-making and course correction.
Quarterly activities
Define a monthly reporting operating rhythm
Build the internal reporting dashboard structure
Finalize the internal reporting dashboard
Present the dashboard to the team
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Operate a disciplined company-wide financial system
Details & activities
Ensure Ramona operates a disciplined, company-wide financial system that supports growth, with clear budget ownership, on-time reviews and approvals, accurate reporting, and consistent monthly closes by the 20th of each month.
Quarterly activities
Define the financial operating model and budget ownership
Implement the Ramp-based spend / approval workflow
Begin finding candidates for a fractional CFO
Continue to execute on closing the books by the 20th of each month
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Operationalize commercial delivery at scale
Activities
Quarterly activities
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined
Activity to be defined

Sources

All data feeds into this dashboard, their cadence, and last upload.

Source Owner File format Feeds Cadence Last uploaded Status
Salesforce Dashboard ExportCommercial / SalesXLS (HTML)Revenue, Pipeline, Revenue vs Target, Pipeline by Stage, Top OpportunitiesMonthlyJun 23, 2026Current
Controller's Monthly Financial ReportOperations / FinanceXLSXNet Burn, Cash Remaining, Gross Margin, Runway, Burn vs Cash PositionMonthlyJun 23, 2026Current
Hiring Plan SpreadsheetOperations / People OpsXLSXHeadcount, Headcount by Function, Hiring Plan, Open RolesMonthlyJun 23, 2026Current
Zoho Helpdesk ExportOperations / SupportCSVCSAT, Happiness Rate, Support OperationsMonthlyJun 23, 2026Current
Annual NPS Survey — Cumulative ResultsOperations / SupportXLSXNPS Score, NPS TrendAnnualJun 12, 2026Current
Employee Satisfaction SurveyOperations / People OpsXLSX (Google Form export)Employee Satisfaction KPIQuarterlyJun 12, 2026Current
Install Base Registry (MCAM)Operations / SupportXLSXInstall Base KPIMonthlyJun 23, 2026Current
MCAM Software AnalyticsEngineering / SoftwareScreenshot (manual)Software Sessions KPI, Cumulative Sessions chartManualManual